

1 **NMICROBIOL-19082155B**

2 Revised version (2020/03/06-2)

3
4 **Structure of polymerized Type V pilin reveals assembly mechanism involving**
5 **protease-mediated strand-exchange**

6
7 Satoshi Shibata^{1,†}, Mikio Shoji^{2,†}, Kodai Okada³, Hideyuki Matsunami¹, Melissa M.
8 Matthews¹, Katsumi Imada^{3,*}, Koji Nakayama^{2,*} and Matthias Wolf^{1,*}

9
10 ¹Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and
11 Technology Graduate University, Okinawa, Japan.

12 ²Department of Microbiology and Oral Infection, Graduate School of Biomedical
13 Sciences, Nagasaki University, Nagasaki, Japan.

14 ³Department of Macromolecular Science, Graduate School of Sciences, Osaka
15 University, Osaka, Japan.

16
17 [†]These authors have contributed equally

18 ^{*}Corresponding authors: knak@nagasaki-u.ac.jp (KN), kimada@chem.sci.osaka-u.ac.jp
19 (KI), and matthias.wolf@oist.jp (MW)

20

21 Bacterial adhesion is a general strategy for host-microbe and microbe-microbe
22 interactions. Adhesive pili are essential for colonization, biofilm formation,
23 virulence, and pathogenesis of many environmental and pathogenic bacteria^{1,2}.
24 Members of the class Bacteroidia have unique Type V pili, assembled by
25 protease-mediated polymerization³. *Porphyromonas gingivalis* is the main
26 contributor to periodontal disease and its Type V pili are a key factor for its
27 virulence⁴. However, the structure of the polymerized pilus and its assembly
28 mechanism are unknown. Here, we show structures of polymerized and
29 monomeric states of FimA stalk pilin from *P. gingivalis*, determined by cryo-EM
30 and crystallography. The atomic model of assembled FimA shows that the
31 C-terminal strand of a donor subunit is inserted into a groove in the β -sheet of an
32 acceptor subunit after N-terminal cleavage by the protease, RgpB. The C-terminus
33 of the donor strand is essential for polymerization. We propose a sequential polar
34 assembly mechanism for Type V pili at the cell surface, involving
35 protease-mediated strand-exchange, employed by various Gram-negative species
36 belonging to the class Bacteroidia. Our results reveal functional surfaces related to
37 pathogenic properties of polymerized FimA. These insights may facilitate
38 development of anti-bacterial drugs.

39 Bacterial pili are classified as chaperone-usher, curli, Type IV,
40 sortase-dependent, the recently discovered Type V, and as yet unclassified e-pili^{1,2,5-7}.
41 Type V pili are unique to Gram-negative bacteria belonging to the class Bacteroidia in
42 the phylum Bacteroidetes, and are composed of anchor, stalk, accessory (or adaptor),
43 and tip pilins². These pilins are structurally conserved and have distinct N- and
44 C-terminal domains (NTD and CTD)³. Each domain has a transthyretin-like fold,
45 consisting of seven β -strands arranged in two β -sheets. Based on the conformation of
46 the C-terminal strand in crystal structures, pilins have been classified as either
47 “closed-form” or “open-form”. The C-terminal strand of open-form pilins extends into
48 the solvent and is not stabilized by crystal contacts³. In analogy to donor-strand

49 exchange in chaperone-assisted pilus assembly^{2,8}, we refer to the monomeric
50 “closed-form”³ of FimA, in which the C-terminal strand constitutes part of the CTD
51 β -sheet, as “self-complementing”, and distinguish the polymerized form as
52 “donor-strand exchanged”.

53 *Porphyromonas gingivalis* belongs to the class Bacteroidia and is a major oral
54 pathogen, associated not only with development and progression of chronic
55 periodontitis in adults⁹, but also several systemic diseases, such as rheumatoid arthritis,
56 cardiovascular disease, and pancreatic cancer¹⁰⁻¹². Recently, *P. gingivalis* has also been
57 implicated in formation of β -amyloid-like deposits in the brain¹³. *P. gingivalis* possesses
58 Type V pili that are either of the long, major Fim pilus type (0.3-1.6 μ m) or the short,
59 minor Mfa type (80-120 nm)^{14,15}, both of which are key virulence factors for host
60 colonization and evasion of the innate immune system^{16,17}. Both types of pili serve to
61 attach cells to oral epithelia via extracellular matrix proteins^{16,17}, as well as in
62 co-aggregation of *P. gingivalis* with other pathogens in the oral biofilm¹⁸.

63 Fim and Mfa pilins are expressed from operons with similar structures,
64 composed of genes encoding stalk pilins (major: FimA or minor: Mfa1), anchor pilins
65 (major: FimB or minor: Mfa2), accessory pilins (major: FimC, FimD, and FimE or
66 minor: Mfa3, Mfa4 and Mfa5), and regulatory proteins¹⁸⁻²¹. FimA pilins from various *P.*
67 *gingivalis* strains are further classified into five subtypes, one of which is divided into
68 two sets (FimA1-FimA5 and FimA1b) that differ in immunogenicity²²⁻²⁵. FimA of *P.*
69 *gingivalis* ATCC 33277 (FimA1) is the best studied pilin and shares 50-85% sequence
70 identity with other FimA subtypes³.

71 The Lol pathway delivers lipoproteins to the inner leaflet of the outer
72 membrane of Gram-negative bacteria²⁶. During Fim pilus biogenesis, pilins are
73 synthesized in the cytoplasm as lipoprotein precursors containing a signal peptide and a
74 conserved cysteine residue that serves as the lipidation site. Pilins are then exported to
75 the periplasm by the Sec system²⁷, where the signal peptide is cleaved by type II signal
76 peptidase, and the cysteine is conjugated with lipids. Lipidated pilins are presumably

77 transported to the outer membrane surface via lipoprotein-sorting machinery²⁸.
78 However, the precise mechanism, how subunits are exported to the cell surface, is not
79 fully understood²⁹. At the cell surface, an arginine- or lysine-specific protease,
80 R-gingipain (Rgp) or K-gingipain (Kgp), removes an N-terminal portion of the pilin
81 that includes the conserved arginine or lysine cleavage residue and the lipidated
82 cysteine. In this way, pilins mature and assemble into the pilus filament^{28,30,31}. Previous
83 experiments have shown that the C-terminal strand of one pilin interacts with residues
84 in the hydrophobic groove of a neighboring pilin in mature pilus filaments³. These
85 insights and recent crystal structures led to the hypothesis that Type V pili are
86 assembled by a protease-mediated strand-exchange mechanism^{2,3}.

87 We cloned and overexpressed recombinant FimA1 from the Type V pilus of *P.*
88 *gingivalis* strain ATCC 33277 (rFimA) containing residues 20-383 in *Escherichia coli*,
89 and purified and crystalized rFimA in monomeric form at 2.1 Å resolution (Fig. 1)^{3,28,30}.
90 There were two nearly identical molecules in the asymmetric unit, except for loop
91 A1-B1 (residues 39-57) and a loop segment of residues 365-370. The structure
92 comprises two domains, an N-terminal domain (NTD) and a C-terminal domain (CTD),
93 consistent with the crystal structure of the homologous FimA4 (PDB 4q98). Each
94 domain contains two β-sheets with seven β-strands in the NTD and in the CTD,
95 arranged in a characteristic transthyretin-like fold. C-terminal residues 380-383 were
96 disordered (Fig. 1b, dashed red line). The C-terminal donor strand A1'-A2' (Fig. 1b,
97 red) passes under loop A1-B1 (residues 39-57), which contains a conserved protease
98 cleavage site at Arg46 (Fig. 1b). Cleavage of the loop by RgpB removes the safety pin
99 and primes the structure for release of the donor strand. Strand A1' is located at the
100 edge of the CTD β-sheet. It is held in place between the edge of the CTD β-sheet and a
101 short adjacent loop in anti-parallel β-strand conformation (residues 322-326) (Fig. 1b).
102 The anchor strand A1 (Fig. 1b), however, is fully integrated into its β-sheet, suggesting
103 greater stability at this position. FimA1 shows 79% amino acid sequence identity with
104 FimA2 (Extended Data Fig. 1a, aligned with Clustal W³²). *P. gingivalis* strains with

105 FimA2 are most frequently found in severe periodontitis patients, whereas those with
106 FimA1 are most prevalent in *P. gingivalis*-positive, healthy adults. We also determined
107 the crystal structure of FimA2 (residues 31-384) at 1.6 Å resolution and compared it
108 with our structures of FimA1 and previously crystalized FimA4³. Crystal structures of
109 FimA1, FimA2, and FimA4 were very similar overall. However, loop regions show
110 significant structural differences (Extended Data Fig. 1 b-d).

111 Previous studies showed that recombinant Type V pilins can polymerize *in*
112 *vitro*^{31,33}. We found that rFimA monomers self-assemble into long filaments after *in*
113 *vitro* treatment with the arginine-specific protease, RgpB. Negative stain transmission
114 electron microscopy (TEM) of purified rFimA filaments showed a twisted ribbon
115 structure similar to Fim pili isolated from Mfa pilus-defective *mfa1* mutant cells (Fig.
116 2a). We estimated the maximum observed assembly rate of rFimA *in vitro* as ~2.5
117 subunits/min (Extended Data Fig. 2 a-d and source data), with polymerization starting
118 ~5 min after protease cleavage (Extended Data Fig. 2e). The longest filaments reached
119 ~1.2 µm after 1 h. These values are similar to *in vitro* growth rates reported for Type 1
120 pili in *E. coli*³⁴. Two-dimensional (2D) class-average cryo-EM images of the rFimA
121 filament and the Fim pilus, purified from the *mfa1* mutant in amorphous ice, show that
122 their dimensions and secondary structural features are very similar (Fig. 2a;
123 approximate widths, 39 Å and 42 Å, respectively).

124 We performed single-particle cryo-EM analysis and used homogeneous *in*
125 *vitro*-assembled homopolymeric rFimA filaments, because the *mfa1* mutant also
126 expresses accessory pilins such as FimC, FimD, and FimE³⁵. The resulting
127 unsymmetrized cryo-EM electron potential map of the rFimA filament was determined
128 at 3.6 Å resolution (Extended Data Fig. 3 and methods), enabling us to build an atomic
129 model containing three pilin subunits (Fig. 2b and 2c). The fitted atomic model depicts
130 the geometry of the rFimA filament. The rFimA filament formed a right-handed helix
131 (twist 71.0° or 5.1 subunits/turn, rise 66.7 Å or pitch 339 Å/turn). Compared to an
132 additional 3D-reconstruction of the Fim pilus from the *mfa1* mutant, helical parameters

133 of the homopolymeric rFimA filament were almost identical (Extended Data Fig. 4).
134 The electron potential map clearly revealed features of the aromatic Phe48 and its
135 neighboring Ala47 at the new N-terminus of the NTD (Fig. 2d), confirming that the
136 N-terminus was cleaved at Arg46 by RgpB. The reconstructed electron potential
137 corresponding to the donor strand A1'-A2' extended into the acceptor pilin subunit, and
138 the C-terminal Trp383 from the donor pilin subunit was found in the CTD of the
139 acceptor pilin subunit (Fig. 2e). Comparison of the donor-strand exchanged structure of
140 rFimA with its self-complementing structure shows that the donor strand A1'-A2'
141 swings out of the CTD at the loop located at residues 356-359 (Fig. 2f).

142 We mapped non-conserved regions, functional binding sites, and epitopes
143 onto the assembled FimA atomic model (Extended Data Fig. 1e and 1f). FimA binds
144 with salivary molecules (salivary protein, statherin, and a proline-rich protein, PRP-1)
145 and is recognized by three pattern-recognition receptors (CD14, CD11b, and CD18)^{16,36}.
146 The salivary protein and statherin binding regions are distributed on well-conserved
147 surfaces, consistent with saliva-binding capability of FimA1 and FimA2²⁴ (Extended
148 Data Fig. 1). The PRP1 binding site is not conserved. Epitopes recognizing CD14,
149 CD11b, and CD18 map to the CTD of the FimA subunit (Extended Data Fig. 1). *P.*
150 *gingivalis* strains expressing FimA2 induce more severe inflammation than those
151 expressing FimA1³⁷⁻³⁹.

152 In the donor-strand exchanged structure (Fig. 2), the A1'-A2' strand of the
153 donor pilin is relocated to the hydrophobic groove of the acceptor pilin. Removal of the
154 N-terminal β -strand A1 and the A1'-A2' strand from our atomic model exposes grooves
155 traversing both β -sheets of NTD and CTD (termed NTD groove and CTD groove,
156 respectively). Surface properties of these grooves are illustrated in a hydrophobicity
157 map (Fig. 3a). Our structure of the assembled donor-strand exchanged-form pilin
158 confirms that the C-terminal strand A1'-A2' rests in the grooves of the acceptor pilin,
159 restoring the full β -sheet (Fig. 3a). The A1' strand (residues 363-372) is located in the
160 NTD groove (Fig. 3b), and A2' strand (residues 377-383) is inserted into the CTD

161 groove (Fig. 3c). Thus, the extended strand of the donor pilin is oriented by
162 hydrophobic interactions in the grooves of the acceptor pilin and held in place by
163 reintegration into its β -sheets via inter-strand hydrogen bonds.

164 The high thermal stability of the assembled pilus⁴⁰ (ladder pattern in Fig. 3d
165 and 3f after incubation for 10 min in SDS buffer at 80°C) may be explained by
166 increased interactions after strand exchange, as well as the entropic cost of exposing the
167 hydrophobic grooves by strand removal. Donor strand A1' is now found in the NTD
168 groove, replacing the A1 strand (Extended Data Fig. 5a). The donor-strand
169 exchanged-form A1' β -strand is longer than A1 in the self-complementing form and has
170 additional side-chain interactions with the NTD. In addition to the β -sheet interactions
171 and the entropically favorable burial of the hydrophobic groove, which are already
172 present in the A1'-CTD pair of the monomeric, self-complementing form, interactions
173 in A2'-CTD of the donor-strand exchanged form include additional hydrogen-bonding
174 between Trp383 and Gln379 of A2' and the main chain atoms of the CTD. Interestingly,
175 the hydrophilic Gln379 is located at the interior hydrophobic face of A2' (Extended
176 Data Fig. 5a). However, the Q379A mutation did not affect pilus formation (Extended
177 Data Fig. 5b and 5c). In our atomic model, the side chain of Asn366 of A1' is within
178 hydrogen-bonding distance of both the main chain carbonyl oxygen and the side chain
179 carboxy oxygen of Glu83 on the NTD. The geometry of Gln368 suggests a similar
180 hydrogen bond with NTD-Thr80.

181 Interactions outside the hydrophobic cleft are also observed in the pilin model.
182 At the interface between subunits, Tyr186 of the donor subunit is within hydrogen
183 bonding distance of the main chain carbonyl oxygen of acceptor subunit Gln70.
184 Similarly, the side chain amide nitrogen of Gln70 pairs with the backbone carbonyl
185 oxygen of donor subunit Ala185 (Extended Data Fig. 5e and 5f). In their
186 crystallographic unit cells, FimA4 or FimA1 pilins from *Bacteroides eggerthii* were
187 stacked head-to-tail, forming pilus-like filaments, despite still being in an immature

188 conformation³. This suggests that the subunit head-tail interface contributes to relative
189 subunit alignment and stability of the pilus.

190 We tested the effects of C-terminal mutants. Deletion of the three C-terminal
191 residues of FimA1 prevents Fim pilus assembly³. Trp383 at the C-terminus of FimA1 is
192 conserved among FimA subtypes (Extended Data Fig. 1a). We deleted C-terminal
193 residues Trp383, Thr382-Trp383, or Ala381-Trp383 by replacement with a stop codon
194 and found that each of these mutations prevented FimA pilus formation on the cell
195 surface (Fig. 3d and 3e). rFimA1(Δ 383) also failed to polymerize *in vitro* (Extended
196 Data Fig. 5d). This indicates the importance of the C-terminal Trp383 for FimA
197 polymerization. Furthermore, we assessed whether Trp383 is specifically required at
198 this position: Substitutions of Trp383 with aromatic (Phe, Tyr) or hydrophobic (Leu)
199 residues were tolerated, but substitutions with His, Ala, or Gly reduced polymerization
200 significantly (Fig. 3f and 3g). The C-terminus is essential for polymerization. When the
201 donor strand A1' is folded back (self-complementing form), it is unlikely that an
202 incoming strand A2' from another donor pilin would be capable of peeling the donor
203 strand from its β -sheet. Therefore, release of the donor strand A1' following cleavage
204 by RgpB should precede binding of the C-terminus of the next pilin. Indeed, related
205 Type V pilins from other species (BfrFim11 and BthFim1A) have been crystallized with
206 their donor strands released from the CTD while the anchor strand, A1, was still
207 present³, suggesting that the donor strand can flip out from the CTD easily.

208 We noticed that FimA(Δ 383) accumulated in cleaved form in the cell fraction
209 (bands near 40 kDa molecular weight in Fig. 3d iii-iv). Indeed, a dot blot assay using
210 wild-type and mutant cells (Fig. 3h) detected the FimA(Δ 383) protein at the cell surface.
211 Both observations demonstrated that the FimA(Δ 383) protein remained at the cell
212 surface after RgpB cleavage. Furthermore, to test whether the anchor strand is released
213 from the NTD after RgpB cleavage, we created cross-linking mutants by introducing
214 cysteine pairs in the FimA(Δ 383) mutant after substituting all intrinsic cysteines with
215 alanines (Fig. 3i). Cross-linking these mutants with dithio-bis-maleimidoethane

216 (DTME) resulted in apparent increased molecular weight of the FimA band, which was
217 prevented by addition of β -mercaptoethanol (β Me) (Fig. 3j). Furthermore,
218 immuno-TEM of the rFimA filament with anti-His-tag antibody showed gold particles
219 localized at one end of the rFimA filament (Extended Data Fig. 6), suggesting that the
220 His-tagged N-terminal strand was still present in the FimA subunit at the base of the
221 FimA filament. Together, these observations strongly suggest that the anchor strand
222 remains attached to the NTD of FimA after RgpB cleavage.

223 Pilin polymerization relies on sequential elongation from the cell membrane
224 until termination. Simultaneous dissociation of donor and anchor strands would detach
225 the subunit from the cell surface, releasing it into the extracellular environment. Hence,
226 we propose that Type V pili grow from the base (Fig. 4). In *P. gingivalis* strain ATCC
227 33277, which does not express anchor pilin, pili are attached to the cell surface although
228 they are easily removed by vortexing, consistent with our finding that pili remain
229 anchored to the cell membrane during assembly. Pilus assembly is prevented by
230 deletion of Trp383 at the C-terminal end (Fig. 3 d-g, Extended Data 5b and 5d).
231 Furthermore, peptides corresponding to the C-terminal region inhibit assembly of the
232 minor Mfa pilus⁴¹. The fact that binding of these C-terminal residues is essential for
233 polymerization suggests that addition of donor strand A2' to the empty CTD groove of
234 the acceptor pilin precedes replacement of the anchor strand (Fig. 4 III). After A2' fills
235 the CTD groove, A1' may be positioned at the NTD-CTD interface to help trigger
236 release of the anchor strand of the acceptor pilin from its NTD, thereby detaching the
237 acceptor subunit from the cell membrane (Fig. 4 IV). As each stalk pilin subunit is
238 added to the assembled pilus (Fig. 4 V), the initial binding of the A2' strand brings the
239 A1' strand into close proximity to the CTD groove. The length of Type V pili is not
240 strictly regulated and there is a wide distribution³. As long as an ample supply of stalk
241 pilin subunits exists on the cell membrane, pili should be able to continue growing.
242 Binding of a membrane-anchored stalk-pilin multimer to an anchor pilin that does not
243 contain the protease cleavage site, will terminate elongation (Fig. 4 VI-VII). Therefore,

244 the final pilus number and the distribution of pilus lengths may be governed by
245 expression level and relative abundance of each gene product. Pilus polymerization at
246 the cell surface may start from a tip pilin, which lacks the donor strand. However, the
247 mechanism is not clear. It is unlikely that a tip pilin would be incorporated into a pilus
248 at the filament tip after pilus polymerization. The stalk pilin FimA alone is sufficient for
249 pilus assembly *in vivo*⁴⁰. Hence, initiation may not require a tip pilin,⁴⁰, which would
250 result in a mixed population of tipped and untipped pili.

251 Pilin polymerization of Type V pili may be similar to that of chaperone-usher
252 pili with respect to their use of donor-strand exchange^{2,6}. Our hypothesis about the
253 initiating role played by the C-terminal residues in Type V pili is reminiscent of the
254 so-called “P5” residue in chaperone-usher pilus assembly, which binds an accessible
255 hydrophobic pocket in the acceptor groove before displacing a complementing strand
256 donated by the chaperone⁸. However, there are several differences between Type V pili
257 and chaperone-usher pili. Their overall pilin domain structure is different and donor
258 strands of chaperone-usher pilins are N-terminal, while those of Type V pilins are
259 C-terminal. Finally, chaperone-usher pili require chaperone proteins for assembly, while
260 Type V pili appear to be self-assembled with the aid of arginine-specific proteases.

261

262 **Methods**

263

264 **Media and growth condition.** *P. gingivalis* ATCC 33277 cells were grown under
265 anaerobic conditions (80% N₂, 10% CO₂, 10% H₂) at 37°C in enriched brain–heart
266 infusion (BHI) broth or on enriched tryptoseya (TS) agar plates supplemented with 5
267 µg/mL hemin (Sigma) and 0.5 µg/mL menadione (Sigma). Luria–Bertani (LB) broth
268 and LB agar plates were used for growth of *E. coli* strains. Antibiotics were used at the
269 following concentrations: ampicillin (50 or 100 µg/mL for *E. coli*) and erythromycin
270 (Em; 10 µg/mL for *P. gingivalis*).

271

272 **Purification of recombinant FimA and RgpB protease.** The genes, *fimA1* and *fimA2*,
273 of *P. gingivalis* strains ATCC 33277 and TDC60, respectively, were amplified with
274 primer pairs F and R, and then cloned into plasmid pET15b. *E. coli* strain BL21 (DE3)
275 was transformed with this plasmid. Primer sequences are available as supplementary
276 information. Recombinant FimA protein with an N-terminal His-tag was purified by
277 affinity chromatography using Talon resin (Clontech, Takara Bio, Japan) or a His
278 TrapTM HP column (GE Healthcare). His-tagged RgpB protease was expressed in *P.*
279 *gingivalis* strain 662i6H⁴² and purified accordingly.

280

281 **Purification, crystallization, and structure determination of Type I and Type II**

282 **FimA of *P. gingivalis*.** His-FimA1 from strain ATCC 33277 and His-FimA2 (residues
283 20-390) from strain TDC60 were expressed in *E. coli* and crudely purified by affinity
284 chromatography, as described above. Each protein solution was mixed with thrombin to
285 remove the His-tag, and dialyzed in 1 L of buffer A (500 mM NaCl in 50 mM Tris-HCl,
286 pH 8.0) at 4°C for 12 h. The protein solution was loaded onto a His TrapTM HP column
287 (GE Healthcare) to remove uncleaved proteins, and further purified with a High Load
288 26/60 Superdex 200 gel filtration column in 10 mM Tris-HCl and 100 mM NaCl (pH
289 8.0). Peak fractions were collected and concentrated.

290 Crystallization was performed by the sitting-drop, vapor-diffusion method.
291 Crystallization drops were prepared by mixing the FimA1 or FimA2 solution with an
292 equal volume of reservoir solution. Initial screening was carried out using screening kits
293 (Wizard I and II, Cryo I and II (Emerald Biostructures) and Crystal Screen I and II
294 (Hampton Research)), and then conditions were optimized. FimA1 crystals used for
295 X-ray data collection were obtained at 20°C from a drop prepared by mixing 1.5 μ L
296 protein solution (10 mg/mL) containing 20 mM Tris-HCl pH 8.0 / 150 mM NaCl with
297 an equal volume of reservoir solution containing 0.1 M sodium citrate pH 5.6, 1.8 M
298 (NH₄)₂ SO₄ and 0.2 M sodium-potassium tartrate. The FimA1 crystal belongs to an
299 orthorhombic space group of $P2_12_12_1$ with unit cell dimensions of $a = 35.8 \text{ \AA}$, $b = 85.5$

300 Å and $c = 242.6$ Å. FimA2 crystals suitable for X-ray data collection were obtained at
301 20°C from a drop prepared by mixing 1.5 µL protein solution (47 mg/mL) containing 20
302 mM Tris-HCl pH 8.0 and 150 mM NaCl with an equivalent volume of reservoir
303 solution containing 0.1 M HEPES pH 7.5, 2.2 M $(\text{NH}_4)_2 \text{SO}_4$ and 1.5 % (w/v) PEG400.
304 FimA2 was crystallized in an orthorhombic space group of $P2_12_12_1$ with unit cell
305 dimensions of $a = 58.9$ Å, $b = 86.0$ Å and $c = 102.1$ Å.

306 X-ray diffraction data were collected at synchrotron beamline BL32XU and BL41XU in
307 SPring-8 (Harima, Japan). Crystals were soaked in a solution containing 90% (v/v)
308 reservoir solution and 10% (v/v) glycerol for a few seconds, frozen in liquid nitrogen,
309 and mounted under nitrogen gas flow at 100 K for X-ray data collection at a wavelength
310 of 1.000 Å. Diffraction data were processed with MOSFLM⁴³ and scaled with
311 AIMLESS⁴⁴. Initial FimA2 crystal data were calculated by molecular-replacement
312 (MR) with Phaser⁴⁵ using the FimA4 structure (PDB ID: 4q98) as a search model. The
313 atomic model was constructed with Coot⁴⁶ and refined with Phenix.refine⁴⁷ to 1.6 Å.
314 Eleven N-terminal residues, 6 C-terminal residues, and 11 residues (N43-D53) in loop
315 A1-B1 were invisible in the electron density map. The Ramachandran plot statistics
316 indicated that 97.4% and 2.6% residues were in the most favorable and allowed regions,
317 respectively. The initial phase of the FimA1 crystal was obtained by MR using the
318 refined FimA2 structure as a search model. The atomic model of FimA1 was
319 constructed with Coot and refined with Phenix.refine to 2.1 Å. During the refinement
320 process, iterative manual modifications were performed. The Ramachandran plot
321 statistics indicated that 97.7% and 2.2% residues were in the most favorable and
322 allowed regions, respectively. Crystallographic statistics can be found in Extended Data
323 Fig. 7a.

324

325 ***In vitro* assembly of FimA1 pili.** rFimA1 monomers at 1.5 mg/mL concentration were
326 mixed with 1 mg/mL RgpB and incubated at 37°C for 4 h. Protease inhibitors
327 N- α -p-tosyl-L-lysine-chloromethyl ketone hydrochloride (TLCK) and leupeptin were
328 added to the solution at 0.1 mM concentration to stop assembly. Assembled rFimA1
329 filaments were precipitated with 4% (w/vol) polyethylene glycol (PEG-6000), 0.2 M
330 NaCl at 4°C and collected by centrifugation at 21,000g for 30 min at 4°C. Pellets were

331 resuspended with 20 mM Tris-HCl pH 7.5 and dialyzed against 20 mM Tris-HCl pH 7.5.
332 Assembly rate was estimated by length measurement of purified filaments imaged by
333 negative stain TEM after 30 min incubation with RgpB, and after 60 min incubation
334 (Extended Data Fig. 2 b-d). 100 filaments were picked from randomly imaged areas.
335 Experiments were carried out in triplicate. Filaments shorter than 100 nm could not be
336 precipitated.

337

338 **Preparation of Fim pili from the Mfa pilus-defective mutant.** Fim pili from *P.*
339 *gingivalis* KDP225 cells (*mfa1::cepA*)³ were prepared by vesicle-depleted supernatant
340 fractionation, as described previously⁴⁸. Briefly, colonies on a TS agar plate were
341 suspended in phosphate buffered saline, vortexed vigorously, and centrifuged at 5,900g
342 for 15 min at 4°C. The supernatant contained soluble extracellular proteins and outer
343 membrane vesicles. The latter were removed by centrifugation at 88,000g for 60 min at
344 4°C and the supernatant, containing Fim pili was used for further analysis.

345

346 **Immunoelectron microscopy.** An rFimA filament sample was blocked against
347 nonspecific binding with PBS containing 0.2% BSA for 30 min at 4°C, and was then
348 incubated with primary anti-His-tag antibody (MBL, Aichi, Japan) at a 1:100 dilution in
349 PBS containing 0.2% BSA for 1 h. Filaments were precipitated with 4% (w/vol)
350 polyethylene glycol (PEG-6000), 0.2 M NaCl at 4°C and collected by centrifugation at
351 100,000g for 30 min at 4°C. Filaments were resuspended with PBS containing 0.2%
352 BSA and then incubated with secondary goat anti-mouse IgG antibody with 10 nm gold
353 conjugates (Sigma-Aldrich) at 1:20 dilution for 1 h. A 1 µL sample was applied to a
354 carbon-coated EM grid, washed twice with PBS and stained with 1% uranyl acetate.

355

356 **Construction of *P. gingivalis* strains expressing FimA variants with C-terminal**
357 **deletions.** A plasmid *pmfa1mfa2* containing the protein expression system induced by
358 anhydrotetracycline (aTC), *pmfa1mfa2::ermF* with *tetR* and aTC-inducible promoter,

359 was constructed and integrated into the *mfa1 mfa2* gene regions by homologous
360 recombination, resulting in an Mfa pilus-deficient *P. gingivalis* strain. We created four
361 different *P. gingivalis fimA mfa1 mfa2* strains expressing FimA⁺, FimA(Δ383),
362 FimA(Δ382-383), FimA(Δ381-383). PCR products were obtained with primer pairs of
363 FimAFw/FimARv, FimAFw/FimA383Rv, FimAFw/FimA382Rv, and
364 FimAFw/FimA381Rv, respectively. Primer sequences are available as supplementary
365 information. PCR products were cloned into the pUC118 vector (Takara, Japan) and
366 sequenced. The NcoI and SalI DNA fragments from cloned vectors were inserted into
367 the NcoI and SalI region of the *pmfa1mfa2* vector, resulting in *pmfa1mfa2*-FimA⁺,
368 *pmfa1mfa2*-FimA(Δ383), *pmfa1mfa2*-FimA(Δ382-383), *pmfa1mfa2*-FimA(Δ381-383).
369 These plasmids were linearized by SphI digestion and introduced into KDP304 cells
370 (*fimA::tetQ*)⁴⁹ by electroporation. Cells were spread on TS agar containing 10 μg/mL
371 Em and incubated under anaerobic conditions for 7 days. To express various FimA
372 proteins, a preculture in BHI broth was used at a 50-fold dilution to inoculate a new
373 BHI broth containing aTC (100 ng/mL). Cell pellets were resuspended with PBS and
374 mixed with SDS sample buffer containing β-mercaptoethanol. Samples were incubated
375 at 80°C for 10 min. FimA protein was detected by Western blot analysis with anti-FimA
376 antibody.

377

378 **Construction of *P. gingivalis* strains with FimA Trp383 substitutions.** To generate
379 mutated proteins of FimA at Trp383, amplified PCR products with primer pairs
380 confirmAFwNcoI/RvFimAW383F, confirmAFwNcoI/RvFimAW383Y,
381 confirmAFwNcoI/RvFimAW383H, confirmAFwNcoI/RvFimAW383A,
382 confirmAFwNcoI/RvFimAW383G, confirmAFwNcoI/RvFimAW383L, using the ATCC
383 33277 genome as template DNA, were cloned into pUC118 (Takara, Kusatsu, Japan).
384 Primer sequences are available as supplementary information. Cloned DNAs were
385 verified by DNA sequencing analysis. The lower NcoI-SalI fragment from those cloned
386 plasmids was inserted in corresponding sites of plasmid *pmfa1mfa2::ermF* with *tetR* and
387 aTC-inducible promoter. Then, each recombinant plasmid was digested with SphI and

388 introduced into the *fimA::tetQ* (KDP304) strain by electroporation. Transformants were
389 selected on blood agar plates containing 10 µg/mL Em.

390

391 **Construction of FimA(Δ383 Cys-null with K40C K81C, or with K40C K167C).**

392 Full-length mutated genes were synthesized (Integrated DNA technology). DNA
393 sequences are available as supplementary information. Synthetic DNAs were cloned
394 into pUC118. Cloned DNAs were verified by DNA sequencing analysis. Each lower
395 NcoI-SalI fragment from those cloned plasmids was inserted into corresponding sites of
396 plasmid *pmfa1mfa2::ermF* with *tetR* and aTC-inducible promoter. Then, each
397 recombinant plasmid was digested with SphI and introduced into the *fimA::tetQ*
398 (KDP304) strain by electroporation. Transformants were selected on blood agar plates
399 containing 10 µg/mL Em.

400

401 **Cys-Cys cross-linking analysis of the anchor strand with NTD.** To detect Cys-Cys
402 cross bridges of mutated FimA(Δ383) protein, aTC-induced cell pellets were collected
403 and washed once with PBS, and then gently suspended in PBS including 0, 0.1, 0.2,
404 0.4 mM dithio-bis-maleimidoethane (DTME) (Tokyo Chemical Industry, Tokyo, Japan),
405 and then incubated at room temperature for 1 h. Cell pellets were then collected and
406 resuspended in PBS with protease inhibitors and then mixed with SDS sample buffer
407 with or without βME. All samples were incubated at 100°C for 10 min. *fimA::tetQ*
408 TetR-FimA(Δ383 Cys-null with two residues substituted to Cys) were used as test
409 strains. Preculture (0.1 mL) was added to 5 mL of new BHI broth with aTC (100
410 ng/mL) and was anaerobically grown overnight. 100 µL of overnight culture was spun
411 down and the supernatant was discarded. The cell pellet was washed once with PBS and
412 suspended in 100 µL PBS with and without DTME at final concentrations of 0.1, 0.2,
413 0.4 mM. Samples were stored at room temperature for 1 h. Then, samples were spun
414 down at 20,400g at 4°C for 1 min. The cell pellet was dissolved with 60 µL of PBS
415 including 0.1 mM TLCK and 0.1 mM leupeptin. 20 µL of 4X SDS sample buffer with
416 or without βME were added. Samples were heat denatured at 100°C for 10 min. 10 µL
417 of samples were applied in each well.

418

419 **Construction of *P. gingivalis* FimA(Q379A).** To generate mutated protein of
420 FimA(Q379A), amplified PCR product with primer pairs of

421 fimAFwNcoI/fimAG379ARv using ATCC 33277 genome as template DNA was cloned
422 into pUC118 (Takara, Kusatsu, Japan). Primer sequences are available as
423 supplementary information. Cloned DNA was verified by DNA sequencing analysis.
424 The lower NcoI-SalI fragment from the plasmid was inserted into corresponding sites of
425 plasmid *pmfa1mfa2::ermF* with *tetR* and aTC-inducible promoter. Then, the
426 recombinant plasmid was digested with SphI and introduced into *fimA::tetQ* (KDP304)
427 by electroporation. Transformants were selected on blood agar plates containing 10
428 µg/mL Em.

429

430 **Construction of recombinant FimA(Δ 383) and FimA(Q379A) proteins in *E. coli*.**

431 To generate recombinant FimA(Δ 383) and FimA(Q379A) proteins with His-tag in
432 N-terminus, amplified PCR products with primer pairs
433 pET15bFimAFw/pET15bFimAW383stopRv and
434 pET15bFimAFw/pET15bFimAG379ARv using the ATCC 33277 genome as template
435 DNA were cloned into pUC118 (Takara, Kusatsu, Japan). Primer sequences are
436 available as supplementary information. Cloned DNAs were verified by DNA
437 sequencing analysis. Each of the smaller NdeI-BamHI fragments from those cloned
438 plasmids was inserted into corresponding sites of pET15b (Novagen). *E. coli* strain
439 BL21 (DE3) was transformed with each plasmid.

440

441 **Gel electrophoresis and immunoblot analysis.** SDS-PAGE and immunoblot analysis
442 were performed as previously described³. Anti-FimA³ or anti-Hemin-binding-protein-35
443 (HBP35)⁵⁰ rabbit polyclonal primary antibodies was used for dot blots and Western
444 blots. HRP-conjugated secondary antibody (Sigma) was used for detection.

445

446 **Cryo-EM sample preparation and data collection.** Three µL of sample solution was
447 applied to holey carbon grids (Quantifoil 1.2/1.3 Cu 400-mesh) after plasma-cleaning
448 with a Solarus (Gatan, Pleasanton, USA) for 30 s at 25°C in a 23% H₂, 77% O₂ gas mix.
449 Grids were blotted for 3 s at 4°C and 100% relative humidity, then immediately
450 plunge-frozen in liquid ethane with a Vitrobot Mark IV (Thermo Fisher Scientific,
451 Hillsboro, USA (TFS)). Image data were collected on a Talos Arctica TEM (TFS)

452 operating at 200 kV in nanoprobe mode using parallel illumination and coma-free
453 alignment, on a Falcon-3 direct electron detector (TFS) in counting mode at a calibrated
454 magnification of 134,048 \times (corresponding to a pixel size of 1.12 Å at the specimen
455 level) with defocus range from -1.5 to -2.5 μm . The microscope and camera were
456 controlled using EPU software (TFS). Images were recorded as movies at a dose rate of
457 0.77 e/ Å^2 /sec at 40 frame/sec, 60-second exposure, with an accumulated total dose of
458 46 e/ Å^2 . Cryo-EM statistics can be found in Extended Data Fig. 7b.

459

460 **Cryo-EM image processing.** Frames in 1,153 movies were aligned using motioncor2⁵¹,
461 dose-weighted, and summed. 831,459 FimA filament fragments were picked by
462 relion_autopick in RELION 2.1⁵² using a Gaussian blob as template. Particle
463 coordinates were exported to the cisTEM⁵³ software package. All subsequent operations
464 were carried out with cisTEM. Particles were boxed with dimension 384 \times 384 pixel
465 covering 3-4 FimA molecules within a circular mask, followed by 2D classification into
466 50 classes. 159,300 particles from good classes (members of class-average images in
467 which the filament shape was recognizable) were retained. The initial 3D alignment
468 model was created with Spider⁵⁴ by command “MO 3” as a cylinder (diameter 50 Å,
469 length 210 Å), used as an initial template in the auto-refinement function of cisTEM
470 with three 3D classes. 3D classes were qualitatively similar. The class with the highest
471 resolution, containing 118,143 particles, was further split into 3 classes, followed by
472 additional refinement. The best of these 3D classes refined to 3.6 Å resolution,
473 including CTF refinement and likelihood blurring. No symmetry was applied. The final
474 reconstruction contained 61,728 particles. The final figure-of-merit-weighted electron
475 potential map was sharpened with a B-factor of -150 Å^{-1} at 3.6 Å resolution. Resolution
476 was estimated using a Fourier shell correlation between two independently refined half
477 sets as implemented in cisTEM (FSC threshold 0.143) (Extended Data Fig. 3 and 7b).
478 Although the angular distribution of Euler angles showed a strong preference for certain
479 orientations, these were clustered along an arch spanning the hemisphere of the angular

480 plot and all orientations outside this preferred region in the plot were represented by at
481 least one particle image (Extended Data Fig. 3). Absolute hand of the map was
482 validated by docking of the FimA1 crystal structure (see below). The cryo-EM
483 reconstruction of the Fim pilus from the Mfa pilus-deficient mutant was created using
484 the same procedure.

485

486 **Cryo-EM model building and refinement.** The crystal structure of FimA pilin was
487 docked as a rigid body into the cryo-EM density map using *UCSF Chimera*⁵⁵. The
488 initial model (PDB 6JZJ) was manually adjusted, and C-terminal residues in the donor
489 strand were manually built with inverted sequence using Coot⁴⁶. The model containing
490 three FimA molecules was refined using PHENIX_real_space_refine⁴⁷. The
491 hydrophobicity map was colored according to the Kyte-Doolittle scale implemented in
492 *UCSF Chimera*⁵⁶.

493

494 **Data availability**

495 The atomic coordinates of the crystal structures have been deposited into the RCSB
496 Protein Data Bank (FimA1: PDB ID 6JZJ, FimA2: PDB ID 6JZK). The coordinates of
497 the cryo-EM based model have been deposited under PDB ID 6KMF. The cryo-EM
498 map has been deposited into the EM database under accession code EMD-0724.
499 Uncropped gel or Western blot scans from Fig. 3d, 3f, 3h, 3j and Extended Data Fig. 2a,
500 2e, 5b are available as source data Fig 3, source data Extended Data Fig 2, and source
501 data Extended Data Fig 5, respectively. Filament length data used to create Extended
502 Data Fig. 2d is available as source data Extended data Fig 2d. Additional raw data that
503 support the findings of this study are available from the corresponding author upon
504 reasonable request.

505

506 **References**

- 507 1. Allen, W. J., Phan, G. & Waksman, G. Pilus biogenesis at the outer membrane of
508 Gram-negative bacterial pathogens. *Curr Opin Struct Biol* **22**, 500–506 (2012).

- 509 2. Hospenthal, M. K., Costa, T. R. D. & Waksman, G. A comprehensive guide to
510 pilus biogenesis in Gram-negative bacteria. *Nat Rev Microbiol* **15**, 365–379
511 (2017).
- 512 3. Xu, Q. *et al.* A Distinct Type of Pilus from the Human Microbiome. *Cell* **165**,
513 690–703 (2016).
- 514 4. Lamont, R. J. & Jenkinson, H. F. Life below the gum line: pathogenic
515 mechanisms of *Porphyromonas gingivalis*. *Microbiol. Mol. Biol. Rev.* **62**, 1244–
516 63 (1998).
- 517 5. Wang, F. *et al.* Structure of Microbial Nanowires Reveals Stacked Hemes that
518 Transport Electrons over Micrometers. *Cell* **177**, 361-369.e10 (2019).
- 519 6. Filman, D. J. *et al.* Cryo-EM reveals the structural basis of long-range electron
520 transport in a cytochrome-based bacterial nanowire. *Commun. Biol.* **2**, 219
521 (2019).
- 522 7. Lukaszczyk, M., Pradhan, B. & Remaut, H. The Biosynthesis and Structures of
523 Bacterial Pili. *Subcell. Biochem.* **92**, 369–413 (2019).
- 524 8. Remaut, H. *et al.* Donor-Strand Exchange in Chaperone-Assisted Pilus Assembly
525 Proceeds through a Concerted β Strand Displacement Mechanism. *Mol. Cell* **22**,
526 831–842 (2006).
- 527 9. Holt, S. C. & Ebersole, J. L. *Porphyromonas gingivalis*, *Treponema denticola*,
528 and *Tannerella forsythia*: the ‘red complex’, a prototype polybacterial pathogenic
529 consortium in periodontitis. *Periodontol.* **2000** **38**, 72–122 (2005).
- 530 10. Demmer, R. T. & Desvarieux, M. Periodontal infections and cardiovascular
531 disease: the heart of the matter. *J Am Dent Assoc* **137** **Suppl**, 14S-20S; quiz 38S
532 (2006).
- 533 11. Michaud, D. S. *et al.* Plasma antibodies to oral bacteria and risk of pancreatic
534 cancer in a large European prospective cohort study. *Gut* **62**, 1764–1770 (2013).
- 535 12. Leech, M. T. & Bartold, P. M. The association between rheumatoid arthritis and
536 periodontitis. *Best Pr. Res Clin Rheumatol* **29**, 189–201 (2015).
- 537 13. Dominy, S. S. *et al.* *Porphyromonas gingivalis* in Alzheimer’s disease brains:
538 Evidence for disease causation and treatment with small-molecule inhibitors. *Sci*
539 *Adv* **5**, eaau3333 (2019).
- 540 14. Yoshimura, F., Takahashi, K., Nodasaka, Y. & Suzuki, T. Purification and
541 characterization of a novel type of fimbriae from the oral anaerobe *Bacteroides*

- 542 gingivalis. *J Bacteriol* **160**, 949–957 (1984).
- 543 15. Hamada, N., Sojar, H. T., Cho, M. I. & Genco, R. J. Isolation and
544 characterization of a minor fimbria from *Porphyromonas gingivalis*. *Infect*
545 *Immun* **64**, 4788–4794 (1996).
- 546 16. Hajishengallis, G., Shakhathreh, M.-A. K., Wang, M. & Liang, S. Complement
547 Receptor 3 Blockade Promotes IL-12-Mediated Clearance of *Porphyromonas*
548 *gingivalis* and Negates Its Virulence In Vivo. *J. Immunol.* **179**, 2359–2367
549 (2007).
- 550 17. Amano, A. Bacterial adhesins to host components in periodontitis. *Periodontol*
551 *2000* **52**, 12–37 (2010).
- 552 18. Park, Y. *et al.* Short fimbriae of *Porphyromonas gingivalis* and their role in
553 coadhesion with *Streptococcus gordonii*. *Infect Immun* **73**, 3983–3989 (2005).
- 554 19. Sojar, H. T., Hamada, N. & Genco, R. J. Isolation and characterization of
555 fimbriae from a sparsely fimbriated strain of *Porphyromonas gingivalis*. *Appl.*
556 *Environ. Microbiol.* **63**, 2318–2323 (1997).
- 557 20. Hasegawa, Y. *et al.* Anchoring and length regulation of *Porphyromonas*
558 *gingivalis* Mfa1 fimbriae by the downstream gene product Mfa2. *Microbiology*
559 **155**, 3333–3347 (2009).
- 560 21. Nagano, K., Hasegawa, Y., Murakami, Y., Nishiyama, S. & Yoshimura, F. FimB
561 Regulates FimA Fimbriation in *Porphyromonas gingivalis*. *J Dent Res* **89**, 903–
562 908 (2010).
- 563 22. Hamada, S. *et al.* Molecular and immunological characterization of the fimbriae
564 of *Porphyromonas gingivalis*. *Microbiol Immunol* **38**, 921–930 (1994).
- 565 23. Fujiwara, T., Nakagawa, I., Morishima, S., Takahashi, I. & Hamada, S.
566 Inconsistency between the fimbrilin gene and the antigenicity of
567 lipopolysaccharides in selected strains of *Porphyromonas gingivalis*. *FEMS*
568 *Microbiol Lett* **124**, 333–341 (1994).
- 569 24. Nakagawa, I. *et al.* Distribution and molecular characterization of
570 *Porphyromonas gingivalis* carrying a new type of fimA gene. *J Clin Microbiol* **38**,
571 1909–1914 (2000).
- 572 25. Nakagawa, I. *et al.* Identification of a new variant of fimA gene of
573 *Porphyromonas gingivalis* and its distribution in adults and disabled populations
574 with periodontitis. *J Periodontal Res* **37**, 425–432 (2002).

- 575 26. Okuda, S. & Tokuda, H. Lipoprotein Sorting in Bacteria. *Annu. Rev. Microbiol.*
576 **65**, 239–259 (2011).
- 577 27. Korotkov, K. V *et al.* Calcium is essential for the major pseudopilin in the type 2
578 secretion system. *J Biol Chem* **284**, 25466–25470 (2009).
- 579 28. Shoji, M. *et al.* The major structural components of two cell surface filaments of
580 *Porphyromonas gingivalis* are matured through lipoprotein precursors. *Mol*
581 *Microbiol* **52**, 1513–1525 (2004).
- 582 29. Konovalova, A. & Silhavy, T. J. Outer membrane lipoprotein biogenesis: Lol is
583 not the end. *Philosophical Transactions of the Royal Society B: Biological*
584 *Sciences* **370**, (2015).
- 585 30. Nakayama, K., Yoshimura, F., Kadowaki, T. & Yamamoto, K. Involvement of
586 arginine-specific cysteine proteinase (Arg-gingipain) in fimbriation of
587 *Porphyromonas gingivalis*. *J Bacteriol* **178**, 2818–2824 (1996).
- 588 31. Shoji, M. *et al.* Recombinant *Porphyromonas gingivalis* FimA preproprotein
589 expressed in *Escherichia coli* is lipidated and the mature or processed
590 recombinant FimA protein forms a short filament in vitro. *Can J Microbiol* **56**,
591 959–967 (2010).
- 592 32. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: Improving the
593 sensitivity of progressive multiple sequence alignment through sequence
594 weighting, position-specific gap penalties and weight matrix choice. *Nucleic*
595 *Acids Res.* **22**, 4673–4680 (1994).
- 596 33. Lee, J. Y. *et al.* Maturation of the Mfa1 Fimbriae in the Oral Pathogen
597 *Porphyromonas gingivalis*. *Front Cell Infect Microbiol* **8**, 137 (2018).
- 598 34. Nishiyama, M., Ishikawa, T., Rechsteiner, H. & Glockshuber, R. Reconstitution
599 of pilus assembly reveals a bacterial outer membrane catalyst. *Science (80-.)*.
600 **320**, 376–379 (2008).
- 601 35. Nishiyama, S. -i. S. I. *et al.* Involvement of minor components associated with
602 the FimA fimbriae of *Porphyromonas gingivalis* in adhesive functions.
603 *Microbiology* **153**, 1916–1925 (2007).
- 604 36. Hajishengallis, G., Ratti, P. & Harokopakis, E. Peptide mapping of bacterial
605 fimbrial epitopes interacting with pattern recognition receptors. *J Biol Chem* **280**,
606 38902–38913 (2005).
- 607 37. Nakano, K. *et al.* Comparison of inflammatory changes caused by

- 608 Porphyromonas gingivalis with distinct fimA genotypes in a mouse abscess
609 model. *Oral Microbiol. Immunol.* **19**, 205–209 (2004).
- 610 38. Sugano, N. *et al.* Differential cytokine induction by two types of Porphyromonas
611 gingivalis. *Oral Microbiol Immunol* **19**, 121–123 (2004).
- 612 39. Bodet, C., Chandad, F. & Grenier, D. Porphyromonas gingivalis-induced
613 inflammatory mediator profile in an ex vivo human whole blood model. *Clin.*
614 *Exp. Immunol.* **143**, 50–57 (2006).
- 615 40. Nagano, K. *et al.* Porphyromonas gingivalis FimA fimbriae: fimbrial assembly
616 by fimA alone in the fim gene cluster and differential antigenicity among fimA
617 genotypes. *PLoS One* **7**, e43722 (2012).
- 618 41. Alaei, S. R., Park, J. H., Walker, S. G. & Thanassi, D. G. Peptide-Based
619 Inhibitors of Fimbrial Biogenesis in Porphyromonas gingivalis. *Infect. Immun.* **87**,
620 e00750-18 (2019).
- 621 42. Veillard, F. *et al.* Purification and characterisation of recombinant His-tagged
622 RgpB gingipain from Porphyromonas gingivalis. *Biol Chem* **396**, 377–384 (2015).
- 623 43. Batty, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W.
624 iMOSFLM: A new graphical interface for diffraction-image processing with
625 MOSFLM. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **67**, 271–281 (2011).
- 626 44. Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta*
627 *Crystallogr D Biol Crystallogr* **67**, 235–242 (2011).
- 628 45. McCoy, A. J. *et al.* Phaser crystallographic software. *J Appl Crystallogr* **40**, 658–
629 674 (2007).
- 630 46. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development
631 of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486–501 (2010).
- 632 47. Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for
633 macromolecular structure solution. *Acta Crystallogr. Sect. D* **66**, 213–221 (2010).
- 634 48. Chen, T., Nakayama, K., Belliveau, L. & Duncan, M. J. Porphyromonas
635 gingivalis gingipains and adhesion to epithelial cells. *Infect. Immun.* **69**, 3048–56
636 (2001).
- 637 49. Kikuchi, Y. *et al.* Novel stationary-phase-upregulated protein of Porphyromonas
638 gingivalis influences production of superoxide dismutase, thiol peroxidase and
639 thioredoxin. *Microbiology* **151**, 841–853 (2005).
- 640 50. Shoji, M. *et al.* Characterization of hemin-binding protein 35 (HBP35) in

- 641 Porphyromonas gingivalis: its cellular distribution, thioredoxin activity and role
642 in heme utilization. *BMC Microbiol.* **10**, 152 (2010).
- 643 51. Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion
644 for improved cryo-electron microscopy. *Nat. Methods* **14**, 331–332 (2017).
- 645 52. Scheres, S. H. W. Chapter Six - Processing of Structurally Heterogeneous
646 Cryo-EM Data in RELION. in *Methods in Enzymology* (ed. Crowther, R. A.) **579**,
647 125–157 (Academic Press, 2016).
- 648 53. Grant, T., Rohou, A. & Grigorieff, N. cisTEM, user-friendly software for
649 single-particle image processing. *Elife* **7**, (2018).
- 650 54. Frank, J. *et al.* SPIDER and WEB: Processing and Visualization of Images in 3D
651 Electron Microscopy and Related Fields. *J. Struct. Biol.* **116**, 190–199 (1996).
- 652 55. Pettersen, E. F. *et al.* UCSF Chimera—A Visualization System for Exploratory
653 Research and Analysis. *J Comput Chem* **25**, 1605–1612 (2004).
- 654 56. Kyte, J. & Doolittle, R. F. A simple method for displaying the hydrophobic
655 character of a protein. *J Mol Biol* **157**, 105–132 (1982).

656

657 **Acknowledgements**

658 The authors thank J. Potempa (University of Louisville) for kindly providing the
659 His-tagged RgpB expressing *P. gingivalis* strain and S. Aizawa (Prefectural University
660 of Hiroshima) for critically reading the manuscript. We thank Steven D. Aird for
661 technical editing. X-ray diffraction data were collected at synchrotron beamlines
662 BL32XU and BL41XU in SPring-8 (Harima, Japan) with the approval of the Japan
663 Synchrotron Radiation Research Institute (JASRI) (Proposal 2014B1478, 2016A2539,
664 2017A2588 and 2018A2569). This work was supported by the Platform Project for
665 Supporting Drug Discovery and Life Science Research (BINDS) from AMED, under
666 grant number JP18am0101076 (to M.W.), by JSPS KAKENHI Grants JP17K17085 and
667 JP19K10083 (to S.S.), by JSPS KAKENHI Grant JP16H05504 (to K.N., K.I. and M.S.),
668 and by a JSPS KAKENHI Grant JP17K07318 (to H.M.). M.W. was supported by direct
669 funding from Okinawa Institute of Science and Technology Graduate University.

670

671 **Author contributions**

672 S.S., M.S., K.I., K.N., and M.W. conceived and designed experiments. M.S., K.O., and
673 S.S. performed molecular cloning and protein purification. M.S. created mutants. S.S.,
674 H.M., M.M., and M.W. carried out cryo-EM experiments and image processing. H.M.
675 and M.M. built atomic models into cryo-EM maps. K.O. and K.I. performed
676 crystallization experiments and analysis. S.S. wrote the first draft. All authors analyzed
677 results and contributed to writing the paper.

678

679 **Corresponding authors**

680 Correspondence to Koji Nakayama, Katsumi Imada, or Matthias Wolf.

681

682 **Competing Interests**

683 The authors declare no competing interests.

684

685 **Figure legends**

686

687 **Figure 1. Crystal structure of the monomeric, self-complementing form of FimA1**

688 **pilin. a**, Schematic of full-length FimA1 protein architecture. The signal sequence
689 enables export and membrane integration by the Sec system. The conserved cysteine
690 serves as a lipidation site. The RgpB cleavage site is marked with a “scissors” symbol.
691 The β -strands A1 (residues 32-37), A1' (365-374), and A2' (376-383) are depicted as
692 arrows. **b**, The crystal structure of monomeric rFimA1 contains ordered density for
693 Glu30-Gln379. Anchor strand A1 (blue) and donor strand A1'-A2' (red) are in the
694 self-complementing (closed) conformation, in which the C-terminal strand (red) is
695 folded back and securely tucked under the N-terminal loop A1-B1 (blue). The dashed
696 red line indicates the disordered C-terminal end of the A2' polypeptide. The scissors
697 icon and blue sphere mark the RgpB cleavage site at Arg46. Scale bar, 20 Å.

698

699 **Figure 2. Cryo-EM structure of the polymerized, donor-strand-exchanged form of**

700 **FimA1 after RgpB cleavage. a**, Top row: Electron micrographs of negatively stained

701 pili. Scale bar, 100 nm. Both results were reproduced 3 times. Bottom row:
702 Reference-free 2D class averages from cryo-EM images of approximately 2,000 boxed,
703 aligned filament segments. Scale bars, 100 Å. Left column: Self-assembled rFimA
704 filament *in vitro*. Right column: A purified Fim pilus from Mfa pilus-defective mutant.
705 **b**, An iso-electron potential surface representation of cryo-EM reconstruction
706 (contoured at 5.5σ above mean) of an rFimA filament with individual pilin subunits
707 highlighted in color. **c**, Same as B, including a fitted atomic model in ribbon
708 representation. **d**, **e**, Ends of the FimA polypeptide chain. The reconstructed electron
709 potential shows the characteristic shape of N-terminal Phe48 (**d**) and C-terminal residue
710 Trp383 (**e**) in the rFimA filament. **f**, An individual rFimA subunit, showing donor
711 strand A1'-A2' in the donor-strand exchanged conformation. Scale bars (b, c, f), 20 Å.



712


713 **Figure 3. Integration of donor strand A1'-A2' into the acceptor pilin.** **a**, A
714 solvent-excluded surface generated from the atomic model of the donor-strand
715 exchanged form FimA, colored by hydrophobicity. The bound donor strand from the
716 next subunit is shown as a blue tube. **b**, A close-up of the NTD groove with strand A2'.
717 **c**, A close-up of the CTD groove containing strand A1'. Hydrophobic residues and the
718 hydrophilic Gln379 (blue dashed box) on the donor strand are labelled. **d**, Western blot
719 of pilus-defective (*fimA mfa1 mfa2*) mutants expressing FimA with C-terminal deletions.
720 Samples were heated at 80°C for 10 min. Lanes: (i), wild type (ATCC 33277); (ii),
721 FimA⁺; (iii), FimA(Δ 383); (iv), FimA(Δ 382-383); (v), FimA(Δ 381-383). Primary
722 antibodies against FimA. Ladder patterns indicate FimA polymerization. **e**, Electron
723 micrographs of negatively stained pilus-defective mutants expressing FimA with a
724 C-terminal deletion. Labels are the same as in (d). Scale bar, 200 nm. **f**, Western blot of
725 pilus-defective (*fimA mfa1 mfa2*) mutants expressing FimA with C-terminal
726 substitutions. Samples were heated at 80°C for 10 min. Lanes: (ii), FimA⁺; (vi),
727 FimA(W383F); (vii), FimA(W383Y); (viii), FimA(W383H); (ix), FimA(W383A); (x),
728 FimA(W383G); (xi), FimA(W383L). **g**, Electron micrographs of substitution mutants
729 from (f). Labels are the same as in (f). Scale bar, 200 nm. **h**, **i**, **j**, Anchor strand A1 is
730 not released by RgpB cleavage *in vivo*. **h**, Immuno dot blot of wild-type (ATCC 33277)
731 cells, Fim pilus-defective (*fimA*) mutant cells, and pilus-defective (*fimA mfa1 mfa2*)
732 mutants expressing FimA(Δ 383). Primary antibodies against FimA and Hemin binding
733 protein 35 (HBP35), a known surface-attached protein. **i**, We substituted all intrinsic

734 cysteines with alanines in FimA(Δ 383) and created two mutants by introducing cysteine
735 pairs in positions (K40, K81) and (K40, K167) for cross-linking the anchor strand
736 (blue) with adjacent β -strands in the NTD. The cross linker dithio-bis-maleimidoethane
737 (DTME, length 13.3 Å) could bridge the distance. **j**, Western blot of the two mutant
738 strains in (i) subjected to increasing concentrations of DTME, with or without the
739 reducing agent, β -mercaptoethanol (β Me). Samples were heated at 100°C for 10 min.
740 Primary antibodies against FimA. Experiments for (d, f, h) were carried out in duplicate,
741 and for (j) in triplicate. Each image in (e, g) is representative for 30 observations of cells,
742 repeated twice.







743


744 **Figure 4. Model for Type V pilus assembly.** (I) There are three types of pilin (anchor,
745 stalk and tip). All are lipoproteins that are lipidated at a conserved cysteine after
746 removal of the signal sequence during export. Lipid anchors at their N-terminal domains
747 (NTD) attach the subunit to the outer membrane (OM) on the cell surface. We refer to
748 strand A1 (Figure 1) as the anchor strand (black or cyan wavy line). The donor strand
749 (red) of the stalk pilin is folded back in the self-complementing form and secured by the
750 anchor strand (cyan) at the RgpB protease cleavage site. The anchor pilin does not have
751 a protease cleavage site and its donor strand is extended. The tip pilin does not contain a
752 donor strand (white ellipse indicates the unfilled groove in the β -sheet). (II) RgpB
753 cleavage removes the safety pin and releases the donor strand of a stalk pilin, exposing
754 a hydrophobic groove in the C-terminal domain (CTD). The pilin remains
755 membrane-attached with its anchor strand. (III) An adjacent pilin in the same cleaved
756 state binds with its donor strand to the unfilled groove of the receptor CTD of a tip or
757 stalk pilin, releasing (IV) the anchor strand from the NTD and freeing the subunit from
758 the cell membrane. (V) Sequential addition of stalk pilins extends the growing pilus.
759 (VI-VIII) Random binding to a non-cleavable anchor pilin terminates polymerization. If
760 assembly starts without a tip pilin, the end of the pilus will be untipped.




a

Fim pilus

**b****c****f**





a

F1ma1 MKKTKFFLLGLAALAMTACKNDNEAEPEYEGNATTSVVLKTSNSNRAFG-VGD--DESKV
 F1ma2 MKKTKFFLLGLAALAMTACKNDNEAEPEYEGNATTSVVLKTSNSNRAFG-VGD--DESKV
 F1ma3 MKKTKFFLLGLAALAMTACKNDNEAEPEYEGNATTSVVLKTSNSNRAFGNAQ--DEAKV
 F1ma4 MKKTKFFLLGLAALAMTACKNDNEAEPEYEGNATTSVVLKTSNSNRAFG-RVG-DDL--TDAKI
 F1ma5 MKKTKFFLLGLAALAMTACKNDNEAEPEYEGNATTSVVLKTSNSNRAFGTEPNSLDDSDAKI

F1ma1 AKLTWVWYNGEQDEAIKSAENAT---KVEDIKCSAG-QRTLVMWANT---G---AMELVG
 F1ma2 AKLTWVWYNGEQDEAIKSAENAT---KVEDIKCSAG-QRTLVMWANT---G---AMELVG
 F1ma3 AKLTWVWYNGEQDEAIKSAENAT---KVENIKCSAG-QRTLVMWANT---G---GMELAG
 F1ma4 TKLTAWVYAGQDEGIKTVVEEDGVLVKEGIDPKCSGANRVLVVAWH-N---YEITGG
 F1ma5 TKLTAWVYAGQVQEGIKTVEDADVLVKEGIDKCSGANRVLVVAWVDRKMGDAIDFTG

CD14 (115-136)

I (151-162)

F1ma1 KTLAEVVALTTEITMENEQAEGLMRTAEPEYDVTLVAGNNVYGD---GSQGGNQSQDTP
 F1ma2 KTLAEVVALTTEITMENEQAEGLMRTAEPEYDVTLVAGNNVYGD---GSQGGNQSQDTP
 F1ma3 KTLAEVVALTTEITMENEQAEGLMRTAEPEYDVTLVAGNNVYGD---GSQGGNQSQDTP
 F1ma4 KSLNEVALTTEITMENEQANLMTKSKAFTIPGSGNHGMP-G-GTASDNLVSAQTP
 F1ma5 KTLDQVVAHTIQLTQDQNSAKFLMTGSEMAFTIPGTVNYGMPAGIGTTDNLTEGMA

CD11b/CD18 (212-231)

F1ma1 LKIRVHARRMAFTEIKVQNSAAY-DNITYFVPEK---YVGLIAKKQSNLEGGATLVVAADANY
 F1ma2 LEIRVHARRMAFTEIKVQNSQSY-VNNVYFAPEN---IYALVAKKESLLEGGASLANSDDAY
 F1ma3 LEIRVHARRMAFTEIKVETIYNSQSY-AKNVYFAPEN---IYALVAKKESLLEGGASLANSDDAY
 F1ma4 LAVTRVHAGISFRAGVEVNAATQY-QNYSFRPADKIALVAKKDSKITGNSLVSNTRAY
 F1ma5 LKVTRVHAASIQNVTVTFDPQSSNYY-FKPNQ---VAGLICCKKQSKIFGASLDFTGD-V

II (224-228)

III (247-250)

CD11b/CD18 (252-271)

F1ma1 LTDSLTFVNGAATYP---ANYA-NVLPULSRNYYVA---PKADAPQGFVYLEENYSANGGTTI
 F1ma2 LTDSLTFVNGAATYP---ANYT-NVMDLGRDYTEIGAAVYNTKRGFVYLEESTYAAQNAQ-L
 F1ma3 LTDSLTFVNGAATYP---ANYT-NVMDLGRDFTF---PSNNAHQGFVYLEESTYAAQNAQ-L
 F1ma4 LVYQVTP-AGLYTPPAAGETVLEAS-LNTNYAV---GA-GFVILESNYDASNE-L
 F1ma5 LGQVATT-MAAATYP---TSYDNNVSMILTKRYVA---KA-GFYIMESIVQYQNN-L

IV (285-273)

V (285-292)

VI (305-309)

Salivary protein (312-231)

F1ma1 RPVTLLCVYKGLQK-NGADLDAGDQLAAQAQANNAWDEG---KITYPVPLVNFNSNNVITYDSNY
 F1ma2 RPVTLLCVYKGLQK-NGADLDAGDQLAAQAQANNAWDEG---KITYPVPLVNFNSNNVITYDSNY
 F1ma3 RPVTLLCVYKGLQK-NHOGAPLSPENETAAFNAGWADNDPRTYYPVPLVNFNSNNVITYDNGY
 F1ma4 RPVTLLCVYKGLQK-NHOGTFLSSEMTAAFNAGWADNDPRTYYPVPLVNFNSNNVITYGEA
 F1ma5 RPVTLLCVYKGLQK-NHOGNFTLTPALITDAINAGYQDGDG---QITYPVPLVNFNSNNVITYGSAI

statherin (339-372)





VII (359-364)






PRP1 (364-383)




F1ma1 T-PRNKIERNHKKVDIKLITTPGPIGNPENPITESHALLVVKCTVAEWLVGONATV-
 F1ma2 T-PRNKIERNHKKVDIKLITTPGPIGNPENPITESHALLVVKCTVAEWLVGONATV-
 F1ma3 V-ENGKIVRNHKFDINLITTPGPIGNPENPITESHALLVNCVAAWIKGVVQNVIV-
 F1ma4 TQGNKIVRNHHKISLINTGPIGNPENPQANLVTCQVTPWVVVQQAATV-
 F1ma5 T-GLNKILRNHHKISLIVKPGPIGNPEGLDEFANLVNCEVSNWVNGOSATW


a




47




b**e****f**

a**b****c****d****e**









Extended Data Figure 7

a. X-ray data collection and refinement statistics

	FimA1 (PDB 6JZJ)	FimA2 (PDB 6JZK)
Data collection		
Space group	$P2_12_12_1$	$P2_12_12_1$
Cell dimensions		
a, b, c (Å)	35.8, 85.5, 242.6	58.0, 86.0, 102.1
α, β, γ (°)	90, 90, 90	90, 90, 90
Resolution (Å)	48.5-2.1 (2.16-2.10)*	65.8-1.6 (1.63-1.60)
R_{merge}	0.050 (0.397)	0.051 (0.514)
$I / \sigma I$	21.3 (4.4)	13.7 (2.7)
Completeness (%)	100.0 (100.0)	99.9 (99.9)
Redundancy	6.6 (6.9)	4.7 (4.7)
Refinement		
Resolution (Å)	2.1 (2.15)	1.6 (1.6)
No. reflections	44,790 (2,982)	67,987 (2,564)
$R_{\text{work}} / R_{\text{free}}$	18.9/24.0 (24.0/27.9)	17.8/19.5 (25.0/25.4)
No. atoms		
Protein	5,231	2,643
Ligand/ion	21	10
Water	381	351
B -factors		
Protein	39.5	20.3
Ligand/ion	51.3	31.2
Water	40.7	29.8
R.m.s. deviations		
Bond lengths (Å)	0.007	0.005
Bond angles (°)	0.818	0.757

*Values in parentheses are for highest-resolution shell.

One crystal was used for each structure.

b. Cryo-EM data collection, model refinement and validation statistics

	FimA1 (EMD-0724) (PDB 6KMF)
Data collection and processing	
Magnification	95,000x
Voltage (kV)	200
Electron exposure ($e^-/\text{Å}^2$)	46
Defocus range (μm)	-1.5 to -2.5
Pixel size (Å)	1.12
Symmetry imposed	None (C1)
Initial particle images (no.)	159,300
Final particle images (no.)	61,728
Map resolution (Å)	3.6
FSC threshold	0.143
Map resolution range (Å)	2.5 – 4.5
Model Refinement	
Initial model used (PDB code)	6JZJ
Model resolution (Å)	4.0
FSC threshold	0.5
Model resolution range (Å)	4.0 – 4.2
Map sharpening B factor (Å^2)	-150
Model composition	
Non-hydrogen atoms	7,704
Protein residues	1,011
B factors (Å^2)	
Protein	128.9
R.m.s. deviations	
Bond lengths (Å)	0.006
Bond angles (°)	0.89
Validation	
MolProbity score	1.9
Clashscore	5.3
Poor rotamers (%)	0.62
Ramachandran plot	
Favored (%)	86.6
Allowed (%)	13.4
Disallowed (%)	0